BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...

Radiographic TBS is a significant predictor of long-term outcomes in HCC patients post-MWA, with higher scores linked to lower survival rates. Laparoscopic MWA outperforms percutaneous MWA, likely due ...

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis and liver diseases contribute to its high incidence ...

Recurrence beyond Milan criteria predicts worse outcomes after hepatocellular carcinoma resection. Limited recurrence remains ...

Due to the extremely rare overlap of mitochondrial DNA depletion syndrome type 3 and pediatric hepatocellular carcinoma, the case presents daunting therapeutic challenges.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, driven by marked molecular and clinical heterogeneity and ...

Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...

Study shows DAAs and interferon offer similar long-term protection against hepatocellular carcinoma after hepatitis C cure ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally. Often diagnosed at advanced stages, the therapeutic ...